{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:54:30Z","timestamp":1792842870970,"version":"4.5.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.rpth.2024.102584","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T15:19:23Z","timestamp":1728487163000},"page":"102584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Safety and efficacy of direct oral anticoagulants in chronic kidney disease: a meta-analysis"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3531-6243","authenticated-orcid":false,"given":"Daniel","family":"Tham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayhan","family":"Kherani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Kou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei Ye","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Eshaghpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Andrew","family":"Crowther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2024.102584_bib1","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/asheducation-2016.1.188","article-title":"Thrombosis and anticoagulation in the setting of renal or liver disease","volume":"2016","author":"Ribic","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.rpth.2024.102584_bib2","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2024.102584_bib3","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2024.102584_bib4","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.rpth.2024.102584_bib5","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1111\/jth.15800","article-title":"Structural and cellular basis of vitamin K antagonism","volume":"20","author":"Liu","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102584_bib6","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1002\/cpt.2369","article-title":"Association between use of pharmacokinetic-interacting drugs and effectiveness and safety of direct acting oral anticoagulants: nested case-control study","volume":"110","author":"Gronich","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.rpth.2024.102584_bib8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1681\/ASN.2007030308","article-title":"Chronic kidney disease increases risk for venous thromboembolism","volume":"19","author":"Wattanakit","year":"2008","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.rpth.2024.102584_bib9","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1161\/CIRCULATIONAHA.112.113944","article-title":"Association of mild to moderate chronic kidney disease with venous thromboembolism: pooled analysis of five prospective general population cohorts","volume":"126","author":"Mahmoodi","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2024.102584_bib10","doi-asserted-by":"crossref","first-page":"c4249","DOI":"10.1136\/bmj.c4249","article-title":"Low glomerular filtration rate and risk of stroke: meta-analysis","volume":"341","author":"Lee","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.rpth.2024.102584_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0266046","article-title":"Chronic kidney disease and atrial fibrillation: a dangerous combination","volume":"17","author":"Ocak","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.rpth.2024.102584_bib12","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1681\/ASN.2015050535","article-title":"The risk of major hemorrhage with CKD","volume":"27","author":"Molnar","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.rpth.2024.102584_bib13","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102584_bib14","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102584_bib15","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102584_bib16","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102584_bib17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/CIRCULATIONAHA.116.022361","article-title":"Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial","volume":"134","author":"Bohula","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2024.102584_bib18","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex","volume":"145","author":"Carnicelli","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2024.102584_bib19","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2024.102584_bib20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.thromres.2020.11.036","article-title":"Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: a systematic review and meta-analysis","volume":"198","author":"Alhousani","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2024.102584_bib21","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1016\/j.ekir.2021.06.004","article-title":"Prescription of direct oral anticoagulants to patients with moderate-to-advanced CKD: too little or just right?","volume":"6","author":"Liabeuf","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.rpth.2024.102584_bib22","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/17151635211058160","article-title":"The 2020 CCS atrial fibrillation guidelines for pharmacists: top 10 takeaways","volume":"155","author":"Leblanc","year":"2022","journal-title":"Can Pharm J (Ott)"},{"key":"10.1016\/j.rpth.2024.102584_bib23","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.rpth.2024.102584_bib24","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"10.1016\/j.rpth.2024.102584_bib25","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rpth.2024.102584_bib26","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2018.05.005","article-title":"Chronic kidney disease and arrhythmias: highlights from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"94","author":"Wanner","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.rpth.2024.102584_bib31","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.cjca.2020.09.001","article-title":"The 2020 Canadian Cardiovascular Society\/Canadian Heart Rhythm Society Comprehensive Guidelines for the management of atrial fibrillation","volume":"36","author":"Andrade","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.rpth.2024.102584_bib32","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"10.1016\/j.rpth.2024.102584_bib35","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"Schulman","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102584_bib38","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102584_bib39","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nrcardio.2015.83","article-title":"Epidemiology of venous thromboembolism","volume":"12","author":"Heit","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.rpth.2024.102584_bib40","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.rpth.2024.102584_bib33","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.rpth.2024.102584_bib36","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.rpth.2024.102584_bib34","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.rpth.2024.102584_bib41","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1161\/CIRCULATIONAHA.114.014113","article-title":"Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis","volume":"131","author":"Chan","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2024.102584_bib42","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/1060028017694654","article-title":"Safety outcomes of apixaban compared with warfarin in patients with end-stage renal disease","volume":"51","author":"Sarratt","year":"2017","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.rpth.2024.102584_bib43","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.119.044059","article-title":"Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease","volume":"141","author":"Stanifer","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2024.102584_bib44","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/rth2.12083","article-title":"Safety and effectiveness of apixaban compared to warfarin in dialysis patients","volume":"2","author":"Reed","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102584_bib45","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.118.035418","article-title":"Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States","volume":"138","author":"Siontis","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2024.102584_bib46","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.amjmed.2019.06.006","article-title":"Efficacy and safety of oral anticoagulants in patients with atrial fibrillation and stages 4 or 5 chronic kidney disease","volume":"132","author":"Chang","year":"2019","journal-title":"Am J Med"},{"key":"10.1016\/j.rpth.2024.102584_bib47","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/FJC.0000000000000911","article-title":"Efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and chronic kidney disease stage G4: a single-center experience","volume":"76","author":"Heleniak","year":"2020","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.rpth.2024.102584_bib48","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/1060028019897053","article-title":"Characterizing the safety profile of apixaban versus warfarin in moderate to severe chronic kidney disease at a veterans affairs hospital","volume":"54","author":"Herndon","year":"2020","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.rpth.2024.102584_bib49","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.120.006515","article-title":"Comparative effectiveness and safety of oral anticoagulants across kidney function in patients with atrial fibrillation","volume":"13","author":"Yao","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.rpth.2024.102584_bib50","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1681\/ASN.2020111566","article-title":"Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial","volume":"32","author":"De Vriese","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.rpth.2024.102584_bib51","article-title":"Effectiveness and safety of rivaroxaban versus warfarin in Taiwanese patients with end-stage renal disease and nonvalvular atrial fibrillation: a real-world nationwide cohort study","volume":"16","author":"Lin","year":"2021","journal-title":"PloS One"},{"key":"10.1016\/j.rpth.2024.102584_bib52","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1055\/s-0041-1740254","article-title":"Effectiveness and safety of apixaban versus warfarin in venous thromboembolism patients with chronic kidney disease","volume":"122","author":"Cohen","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102584_bib53","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11239-022-02758-7","article-title":"Effectiveness and safety of direct oral anticoagulants in patients with venous thromboembolism and creatinine clearance\u00a0< 30 mL\/min","volume":"55","author":"Cline","year":"2023","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.rpth.2024.102584_bib54","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/jhm.12926","article-title":"Safety and effectiveness of apixaban versus warfarin for acute venous thromboembolism in patients with end-stage kidney disease: a national cohort study","volume":"17","author":"Ellenbogen","year":"2022","journal-title":"J\u00a0Hosp Med"},{"key":"10.1016\/j.rpth.2024.102584_bib55","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial","volume":"146","author":"Pokorney","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2024.102584_bib56","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.122.062779","article-title":"A\u00a0randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study","volume":"147","author":"Reinecke","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2024.102584_bib57","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.113.003628","article-title":"Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis","volume":"129","author":"Hijazi","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2024.102584_bib58","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/phar.1905","article-title":"Comparison of the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment","volume":"37","author":"Stanton","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.rpth.2024.102584_bib59","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1160\/TH17-03-0176","article-title":"Dabigatran versus warfarin for acute venous thromboembolism in elderly or impaired renal function patients: pooled analysis of RE-COVER and RE-COVER II","volume":"117","author":"Goldhaber","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102584_bib60","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1177\/1060028018781853","article-title":"Safety and efficacy of apixaban versus warfarin in patients with advanced chronic kidney disease","volume":"52","author":"Schafer","year":"2018","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.rpth.2024.102584_bib61","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.2215\/CJN.13811217","article-title":"Risks and benefits of direct oral anticoagulants across the spectrum of GFR among incident and prevalent patients with atrial fibrillation","volume":"13","author":"Shin","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.rpth.2024.102584_bib62","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.hrthm.2017.10.033","article-title":"Renal function and risk of stroke and bleeding in patients undergoing catheter ablation for atrial fibrillation: comparison between uninterrupted direct oral anticoagulants and warfarin administration","volume":"15","author":"Yanagisawa","year":"2018","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.rpth.2024.102584_bib63","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ahj.2020.01.010","article-title":"Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease","volume":"223","author":"Weir","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.rpth.2024.102584_bib64","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/bloodadvances.2019000972","article-title":"Outcomes associated with apixaban vs warfarin in patients with renal dysfunction","volume":"4","author":"Hanni","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2024.102584_bib65","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.amjcard.2019.10.033","article-title":"Safety and efficacy of direct oral anticoagulants versus warfarin in patients with chronic kidney disease and atrial fibrillation","volume":"125","author":"Makani","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.rpth.2024.102584_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.752468","article-title":"Apixaban vs. warfarin in atrial fibrillation patients with chronic kidney disease","volume":"8","author":"Fu","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.rpth.2024.102584_bib67","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ijcard.2021.10.025","article-title":"New evidence of direct oral anticoagulation therapy on cardiac valve calcifications, renal preservation and inflammatory modulation","volume":"345","author":"Di Lullo","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.rpth.2024.102584_bib68","article-title":"Oral factor\u00a0Xa inhibitors versus warfarin for the treatment of venous\u00a0thromboembolism in advanced chronic kidney disease","volume":"2021","author":"Ahuja","year":"2021","journal-title":"Adv\u00a0Hematol"},{"key":"10.1016\/j.rpth.2024.102584_bib69","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/1076029611433769","article-title":"Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III\/IV lung cancer","volume":"18","author":"Haas","year":"2012","journal-title":"Clin Appl Thromb Hemost"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924002796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924002796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T19:23:07Z","timestamp":1732216987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037924002796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":63,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2475037924002796"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102584","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of direct oral anticoagulants in chronic kidney disease: a meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102584","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102584"}}